SAB Biotherapeutics, Inc. Warrant financials
$0.0140−4.10%
Close Sep 28, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $114.7K | $0.00 | $263.1K | $944.6K | $305.0K | $1.3M |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $114.7K | $0.00 | $263.1K | $944.6K | $305.0K | $1.3M |
| Gross margin | — | — | — | — | — | — | 100.0% | — | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$23.4M | -$20.0M | -$15.8M | -$12.7M | -$9.7M | -$10.8M | -$10.0M | -$11.3M | -$10.2M | -$11.4M | -$18.9M | -$5.3M |
| Net income | -$22.5M | -$18.9M | -$2.8M | $5.3M | -$10.1M | -$5.2M | -$11.4M | -$10.3M | -$7.3M | -$5.0M | -$22.9M | -$5.1M |
| Net margin | — | — | — | — | — | — | −9934.5% | — | −2787.7% | −532.1% | −7493.8% | −402.6% |
| Diluted EPS | $-0.28 | $-0.35 | $-0.02 | $-0.21 | $-1.09 | $-0.56 | $-1.23 | $-1.12 | $-0.79 | $-0.54 | $-3.38 | $-0.97 |
| EBITDA | -$22.6M | -$19.3M | -$15.0M | -$11.9M | -$9.0M | -$10.0M | -$9.2M | -$10.3M | -$9.2M | -$9.4M | -$17.9M | -$4.4M |
| Operating cash flow | -$9.8M | -$14.3M | -$16.8M | -$13.1M | -$7.2M | -$7.8M | -$9.5M | -$6.3M | -$7.7M | -$10.8M | -$13.4M | -$5.2M |
| Free cash flow | -$11.4M | -$15.3M | -$17.7M | -$13.1M | -$7.2M | -$7.8M | -$9.6M | -$6.4M | -$7.8M | -$10.9M | -$13.5M | -$5.3M |
| Diluted shares | 79.8M | 53.6M | 148.9M | 77.9M | 9.3M | 9.3M | 9.3M | 9.3M | 9.3M | 9.2M | 6.8M | 5.2M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $8.3M | $20.5M | $10.5M | $29.4M | $3.7M | $5.6M |
| Short-term investments | $94.4M | $88.4M | $86.1M | $82.0M | $2.0M | $7.2M |
| Total debt | $3.2M | $3.2M | $3.3M | $3.3M | $3.3M | $3.5M |
| Total assets | $238.2M | $248.5M | $172.8M | $183.4M | $30.1M | $38.1M |
| Total liabilities | $23.4M | $21.2M | $21.3M | $18.4M | $18.1M | $16.7M |
| Shareholders' equity | $214.8M | $227.2M | $151.5M | $165.1M | $12.0M | $21.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology